Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Daijiro Harada"'
Autor:
Shoichi Kuyama, Kenichiro Kudo, Toshio Kubo, Nobukazu Fujimoto, Akihiro Bessho, Yoshinobu Maeda, Naoyuki Nogami, Makoto Sakugawa, Katsuyuki Hotta, Kadoaki Ohashi, Takashi Ninomiya, Katsuyuki Kiura, Daijiro Harada, Keisuke Aoe, Eiki Ichihara, Daisuke Minami, Keisuke Sugimoto, Nobuaki Ochi, Toshiyuki Kozuki, Nagio Takigawa
Publikováno v:
Japanese Journal of Clinical Oncology. 51:1269-1276
Background In a phase I study, afatinib (30 mg/body daily) plus bevacizumab (15 mg/kg every 3 weeks) was well tolerated and showed favourable outcomes in patients with epidermal growth factor receptor (EGFR)-mutant advanced non-small-cell lung cancer
Autor:
Keisuke Aoe, Shoichi Kuyama, Koji Inoue, Kazuhiro Yatera, Takayuki Suetsugu, Minoru Fukuda, Nobukazu Fujimoto, Kosuke Kashiwabara, Noriyuki Ebi, Fumihiro Tanaka, Daijiro Harada, Akihiro Nishiyama, Chiharu Yoshii, Hitomi Umeguchi, Hironori Yoshida, Atsushi Kawaguchi, Chiho Nakashima, Katsumi Nakatomi, Kentaro Iwanaga, Ayako Takamori, Genju Koh, Naoko Sueoka-Aragane, Nobuhiko Seki, Hidetaka Uramoto, Naohisa Matsumoto, Sunao Ushijima, Kaname Nosaki
Publikováno v:
Cancer Medicine, Vol 10, Iss 12, Pp 3873-3885 (2021)
Cancer Medicine
Cancer Medicine
Background EGFR mutations are good predictive markers of efficacy of EGFR tyrosine kinase inhibitors (EGFR‐TKI), but whether comprehensive genomic analysis beyond EGFR itself with circulating tumor DNA (ctDNA) adds further predictive or prognostic
Autor:
Naoyuki Nogami, Shunta Mori, Yumi Asakura, Daijiro Harada, Kenji Takata, Takayuki Ohno, Satoko Moriki, Toshiyuki Kozuki, Yoshika Takechi
Publikováno v:
Anticancer Research. 39:4987-4993
Background/aim For immune checkpoint inhibitor (ICI)-pretreated patients, docetaxel and ramucirumab (DOC+RAM) combination therapy may be more effective compared to patients not receiving ICI treatment. Patients and methods From June 2013 to July 2018
Autor:
Tsuyoshi, Ueno, Yuho, Maki, Ryujiro, Sugimoto, Hiroshi, Suehisa, Motohiro, Yamashita, Daijiro, Harada, Toshiyuki, Kozuki, Naoyuki, Nogami
Publikováno v:
Acta Medica Okayama. 73(4):325-331
Therapeutic approaches to bronchopleural fistula (BPF) closure after lung resection are surgical or endoscopic interventions. We evaluated therapeutic outcomes to determine the optimal approach. We reviewed 15 patients who had developed BPF after lun
Autor:
Takuo Shibayama, Yoshinobu Maeda, Shingo Harita, Naofumi Hara, Koji Inoue, Shinobu Hosokawa, Eiki Ichihara, Akihiro Bessho, Katsuyuki Kiura, Naohiro Oda, Katsuyuki Hotta, Daizo Kishino, Daijiro Harada, Nobuaki Ochi
Publikováno v:
Japanese journal of clinical oncology. 51(2)
Objectives Studies investigating the association between radiation therapy and the efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer have provided inconsistent results, likely due to relatively small cohort sizes. This s
Autor:
Daijiro Harada, Junji Kishimoto, Katsuyuki Hotta, Tatsuro Fukuhara, Kazuko Sakai, Makoto Nishio, Kazuto Nishio, Takayuki Shimose, Kaname Nosaki, Koichi Azuma, Hiroaki Akamatsu, Isamu Okamoto, Takayasu Kurata, Yoichi Nakanishi, Eiji Iwama, Koichi Goto
Publikováno v:
Cancer Science
Liquid biopsy offers a potential alternative to tissue biopsy for detection of genetic alterations in cancer, and it has been introduced into clinical practice to detect the tyrosine kinase inhibitor (TKI) resistance-conferring T790M mutation of epid
Autor:
Katsuyuki Hotta, Toshio Kubo, Katsuyuki Kiura, Shoichi Kuyama, Daijiro Harada, Keisuke Aoe, Keisuke Sugimoto, Kadoaki Ohashi, Takuo Shibayama, Nagio Takigawa, Naoyuki Nogami, Nobuaki Fukamatsu, Takashi Ninomiya, Toshiyuki Kozuki, Nobukazu Fujimoto, Kenichiro Kudo, Akihiro Bessho
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 115
Objective In advanced epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC), treatment with afatinib, a second-generation EGFR-tyrosine kinase inhibitor (TKI), confers a significant survival benefit over platinum-based che
Autor:
Masamoto Nakanishi, Katsuyuki Kiura, Daijiro Harada, Toshio Kubo, Shoichi Kuyama, Toshiaki Okada, Daizo Kishino, Kadoaki Ohashi, Nobuaki Ochi, Tomoko Yamagishi, Takahiro Umeno, Genyo Ikeda, Eiki Ichihara, Mitsune Tanimoto, Kenichi Chikamori, Nobukazu Fujimoto, Nagio Takigawa, Akihiro Bessho, Katsuyuki Hotta
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 112
Introduction S-1 is an oral fluoropyrimidine-based combination of tegafur, gimeracil, and oteracil potassium. Although the combination of S-1 with carboplatin is a first-line chemotherapy regimen for advanced non-small cell lung cancer (NSCLC), the e
Autor:
Hiroshi, Suehisa, Fumio, Matsuda, Hiroaki, Kawamoto, Tsuyoshi, Ueno, Shigeki, Sawada, Motohiro, Yamashita, Shoichiro, Yamamoto, Daijiro, Harada, Hiromoto, Kitajima, Toshiyuki, Kozuki, Naoyuki, Nogami, Hiroyuki, Takahata
Publikováno v:
Kyobu geka. The Japanese journal of thoracic surgery. 67(7)
A 54-year-old man with pulmonary non-tuberculous mycobacteriosis( pulmonary NTM) who had been treated by antituberculous chemotherapy, developed a new nodule of 1.3 cm in size in the segment 1/2 of the right upper lobe. The cavity of 3.5 cm in size i